安罗替尼联合化疗治疗晚期非小细胞肺癌的疗效及毒副作用分析  

Analysis the Efficacy and Side Effects of Anrotinib Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：周晓蕾[1] 邝红萍 袁彦丽 张娟[1] 汤兵祥[1] 张曼林[1] ZHOU Xiaolei;KUANG Hongping;YUAN Yanli;ZHANG Juan;TANG Bingxiang;ZHANG Manlin(Henan Provincial Chest Hospital, Henan Zhengzhou 450000, China)

机构地区：[1]河南省胸科医院,河南郑州450000

出　　处：《中国医药导刊》2020年第7期456-459,共4页Chinese Journal of Medicinal Guide

基　　金：河南省医学科技攻关计划联合共建项目(项目编号:2018020544,项目名称:数据挖掘技术在肺小结节诊断中的价值);河南省医学科技攻关计划联合共建项目(项目编号:2018020542,项目名称:炎症小体NLRP3及NLRP12与肺癌的相关性研究)。

摘　　要：目的:探讨安罗替尼联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法:回顾性分析我院2018年5月至2019年10月期间收治的60例晚期非小细胞肺癌患者,按不同治疗方案分为两组,即对照组(n=30),单纯化疗治疗;观察组(n=30),安罗替尼联合化疗治疗。比较两组患者近期治疗效果、生存质量改善情况及毒副反应情况。结果:观察组患者近期总有效率83.33%,高于对照组的53.33%(P<0.05);观察组患者生存质量改善率56.67%,高于对照组的26.67%(P<0.05)。两组患者不良反应分级Ⅰ~Ⅱ级,观察组患者手足综合征发生率高于对照组患者(P<0.05),神经系统、皮下和皮肤组织损害发生率低于对照组患者(P<0.05),其余不良反应发生率比较差异无统计学意义(P>0.05)。结论:安罗替尼联合化疗治疗晚期非小细胞肺癌获得显著近期效果,生存质量改善明显,并不会增加患者的毒副反应。Objective:To investigate the efficacy and side effects of anrotinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer.Methods:Retrospective analysis was performed on 60 patients with advanced NSCLC admitted to our hospital from May 2018 to October 2019.They were divided into two groups according to different treatment regimens,namely the control group(n=30),which was treated with chemotherapy,and the observation group(n=30),which was treated with anrotinib combined with chemotherapy.The short-term effect,improvement rate of quality of life and adverse reactions of the two groups were compared.Results:The short-term total effective rate of the observation group was 83.33%,higher than that of the control group(53.33%),and the improvement rate of the quality of life of the observation group was 56.67%,higher than that of the control group(26.67%),the difference was statistically significant(P<0.05).The classification of adverse reactions of the two groups was classⅠ-Ⅱ.The incidence race of hand-foot syndrome of the observation group was higher than that of the control group(P<0.05).The nervous system,skin and subcutaneous tissue damage rate of the observation group was lower than that of the control group(P<0.05).There was no statistical difference in the incidence of the rest adverse reactions of the two groups(P>0.05).Conclusion:The combination of anrotinib and chemotherapy in the treatment of advanced non-small cell lung cancer has a significant short-term effect,and the quality of life has been improved significantly without increassing adverse effects.

关 键 词：安罗替尼 化疗 晚期非小细胞肺癌 毒副作用 

分 类 号：R73[医药卫生—肿瘤]